Q4 2025 Praxis Precision Medicines Inc Earnings Call Transcript
Key Points
- Praxis Precision Medicines Inc (PRAX) achieved significant clinical and regulatory advancements in 2025, including positive results for multiple drugs and two NDA submissions.
- The company received breakthrough designation from the FDA for elixacalmide, highlighting its potential as a novel treatment for essential tremor.
- Praxis is well-capitalized with approximately $1.5 billion in cash, expected to fund operations into 2028, providing a strong financial foundation for future growth.
- The company is preparing for the commercial launch of elixacalmide, with a comprehensive medical education campaign and key hires to support the launch.
- Praxis has a robust pipeline with multiple upcoming clinical readouts and potential market opportunities exceeding $20 billion across its CNS portfolio.
- Operating expenses increased significantly in 2025, driven by higher R&D and G&A costs, which may impact profitability in the short term.
- The company faces challenges in ensuring a smooth review process with the FDA for its NDA submissions, which could affect approval timelines.
- There is uncertainty regarding the final label for elixacalmide, particularly concerning alternative titration schedules, which could impact prescriber guidance.
- Praxis is focusing primarily on the U.S. market, potentially limiting its global reach and market penetration in the short term.
- The competitive landscape in epilepsy and CNS disorders is evolving, with potential new entrants that could impact Praxis's market share and revenue projections.
Good day and thank you for standing by. Welcome to the Praxis Precision Medicine's 4th quarter in full year 2025 earnings call.
At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone.
You will then hear an automated message advising your hand is raised to withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Dan Ferry investor relations. Please go ahead.
Good morning and welcome to the Practice Precision medicine's 4th quarter and full year 2025 financial results and business update conference call.
This call is being webcast live and can be accessed on the investors section of Practice website at www.practicemedicines.com.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
